AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01344824
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
Trial: NCT00596687
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily SQ
Trial: NCT00596687
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: scheduled glulisine given SQ at mealtime TID; none given if patient NPO
Trial: NCT01209949
Drug: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply adapalene BPO gel once daily in the evening for 12 weeks
Trial: NCT00168363
Drug: brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02395848
Drug: Fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
Trial: NCT00729612
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00729612
Drug: paclitaxel albumin-stabilized nanoparticle formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03030560
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
Trial: NCT03030560
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
Trial: NCT00300885
Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
RxNorm normalized name: Nexavar
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
Trial: NCT00300885
Drug: Carboplatin plus Paclitaxel
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
Trial: NCT01019395
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
Trial: NCT00093314
Drug: HuMax-CD20
RxNorm normalized name: HuMax-CD20
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00789373
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
Trial: NCT00789373
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
Trial: NCT00789373
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
Trial: NCT01707966
Drug: Orteronel
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03244930
Drug: Plerixafor 0.12 mg/kg
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
Trial: NCT03433196
Drug: HS-25 and Atorvastatin
RxNorm normalized name: atorvastatin and amlodipine
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
Trial: NCT03433196
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
Trial: NCT00607074
Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
RxNorm normalized name: Giardia lamblia
DrugBank: Lamb (DB10537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Trial: NCT00607074
Drug: Anti-Giardia treatment only (secnidazole or albendazole)
RxNorm normalized name: Giardia lamblia
DrugBank: Lamb (DB10537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Trial: NCT00405431
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in study eye twice a day X 6 months
Trial: NCT00405431
Drug: Endura (artificial tears)
DrugBank: Boscalid (DB12792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in study eye twice a day X 6 months
Trial: NCT03512210
Drug: Sofosbuvir/Velpatasvir (SOF/VEL)
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
Trial: NCT04042623
Drug: AVB-S6-500
RxNorm normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB-S6-500 is experimental drug
Trial: NCT03421210
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
Trial: NCT00502112
Drug: lintuzumab
RxNorm normalized name: Lintuzumab
DrugBank: Lintuzumab (DB14877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
Trial: NCT00502112
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
Trial: NCT00225524
Drug: Effexor XR
RxNorm normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03412734
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine preparation solutions
Trial: NCT03412734
Drug: Iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine-based preparation solutions
Trial: NCT00570193
Drug: verteporfin (Visudyne)
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
Trial: NCT00570193
Drug: ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol
Trial: NCT00694083
Drug: Ridaforolimus
RxNorm normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
Trial: NCT02249728
Drug: oral 14C-PBT2
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00017082
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002691
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002691
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00169611
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04483960
Drug: (Arm Closed) Nafamostat Mesilate
RxNorm normalized name: mesylate
DrugBank: Nafamostat (DB12598)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
Trial: NCT04483960
Drug: (Arm Closed) Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.
Trial: NCT04483960
Drug: (Arm Closed) Dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.
Trial: NCT04483960
Drug: (Arm Closed) Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).
Trial: NCT04483960
Drug: Nirmatrelvir-Ritonavir
RxNorm normalized name: nirmatrelvir-ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
Trial: NCT04483960
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
Trial: NCT00179660
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules for oral administration.
Trial: NCT04062201
Drug: Bedaquiline Oral Tablet
RxNorm normalized name: bedaquiline Oral Tablet
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - \>50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
Trial: NCT04062201
Drug: Linezolid Oral Tablet
RxNorm normalized name: linezolid Oral Tablet
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
Trial: NCT04062201
Drug: Delamanid in Oral Dosage Form
RxNorm normalized name: osage orange pollen extract
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - \>50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
Trial: NCT04062201
Drug: Clofazimine Oral Product
RxNorm normalized name: clofazimine Oral Product
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
Trial: NCT04062201
Drug: Levofloxacin Oral Tablet
RxNorm normalized name: levofloxacin Oral Tablet
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
Trial: NCT04062201
Drug: Isoniazid Oral Product
RxNorm normalized name: isoniazid Oral Product
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group \>50kg: 600mg daily
Trial: NCT04062201
Drug: Ethambutol Oral Product
RxNorm normalized name: ethambutol Oral Product
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group \>50kg: 1200mg daily
Trial: NCT04062201
Drug: Pyrazinamide Oral Product
RxNorm normalized name: pyrazinamide Oral Product
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group \>50kg: 2000mg daily
Trial: NCT01210846
Drug: tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
Trial: NCT02744430
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
Trial: NCT02282813
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
Trial: NCT02282813
Drug: Doxercalciferol
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
Trial: NCT02282813
Drug: Paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
Trial: NCT02541513
Drug: paliparidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
Trial: NCT00098436
Drug: laromustine
RxNorm normalized name: Laromustine
DrugBank: Laromustine (DB05817)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098436
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02196441
Drug: 2% tetracaine local anaesthetic drops
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical anaesthetic drops
Trial: NCT02196441
Drug: 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
Trial: NCT03645395
Drug: MT-3724
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment with MT-3724 in combination with LEN therapy.
Trial: NCT02088671
Drug: Propofol induction followed by randomized doses of desflurane
RxNorm normalized name: Desflurane
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
Trial: NCT02847091
Drug: Ipragliflozin
RxNorm normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral administration, 50mg once daily
Trial: NCT02847091
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
Trial: NCT04346667
Drug: Hydroxychloroquine Sulfate Regular dose
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Trial: NCT04346667
Drug: Hydroxychloroquine Sulfate Loading Dose
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine administered as a loading dose only
Trial: NCT04346667
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2